SENSEX    73730.16       -609.28    |    NIFTY    22419.95       -150.40 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
Coal India, APSEZ, Torrent Pharma, HDFC Life Insurance in focus
31-May-23   08:46 Hrs IST

Coal India: The board of directors of Coal India has approved revision of Non-Coking coal prices with effect from 31st May 2023. The board has approved price increase of 8% over the existing notified prices for high grade coal of grade G2 to G10. Due to this revision, Coal India will earn approx. incremental revenue of Rs 2703 crore for the balance period of financial year 2023-24.

Adani Ports and Special Economic Zone (APSEZ): The company reported consolidated net profit of Rs 1,140.99 crore in Q4 FY23 as against a net profit of Rs 1,111.63 crore in Q4 FY22. Total income rose to Rs 6,179.12 crore in the quarter ended 31 March 2023 from Rs 4,739.08 crore recorded in Q4 FY22.

Torrent Pharmaceuticals: The company reported consolidated net profit of Rs 287 crore in Q4 FY23 as against a net loss of Rs 118 crore in Q4 FY22. Total income rose to Rs 2500 crore in the quarter ended 31 March 2023 from Rs 2187 crore recorded in Q4 FY22.

Mankind Pharma: The company's consolidated net profit rose 52% to Rs 294 crore in Q4 FY23 as against a net profit of Rs 193 crore in Q4 FY22. Revenue from operations rose 19% to Rs 2053 crore in the quarter ended 31 March 2023 from Rs 1726 crore recorded in Q4 FY22.

HDFC Life Insurance Company: UK-based investment company Abrdn is reportedly likely to sell its entire 1.66% equity in HDFC Life Insurance Company via block deals.

Lupin: The pharma major announced a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab.

Powered by Capital Market - Live News
MARKETS
TODAY'S MARKET SECTOR
BSE NSE
Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.86 89.11 1.07
United Kingdom (GBP) 1.16 1.00 103.70 1.24
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.93 0.80 83.31 1.00
Market News << ALL News
  26-Apr-2024, (05:07 )  Maruti Suzuki Q4 PAT..
  26-Apr-2024, (04:47 )  Motilal Oswal Financ..
  26-Apr-2024, (04:40 )  Dolat Algotech hits ..
  26-Apr-2024, (03:50 )  Shriram Finance PAT ..
 Commodities << ALL Commodities
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
   Disclaimer   |   BSE Disclosure  |  Privacy Policy   |   Investor Protection   |    Inactive Account   |  Vernacular Language: NSE | BSE   |   Feedback   |    PMLA Policy   |   Risk Management Policy   |   Insider Trading   |   Investor Grivenances   |   Investor Complaints   |   Investor Charter   |   Rules And Regulations   |   Broker Norms   |   Terms of Use    Policies & Procedures   |   Risk Disclosure   |   Do & Don’ts   |   Rights & Obligations
  
SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)